Company News: Page (1) of 1 - 12/09/17 Email this story to a friend. email article Print this page (Article printing at page facebook

IMBRUVICAŽ (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

- Nearly half of all R/R MCL patients in the pooled analysis were able to survive their disease at three years and more than one quarter of patients had no progression in their disease- Median PFS out... (December 09, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business Issues,Presentation,People,Events,OS (Operating System),England,USA,Medicine,Disease,Surgery,Pregnancy,Cancer,Surgery,Pregnancy,Science,Medical,Biology,Cancer,england,Other,Men,Women,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved